Table of Contents
Metal-Based Drugs
Volume 2010 (2010), Article ID 207084, 11 pages
http://dx.doi.org/10.1155/2010/207084
Review Article

Hypersensitivity Reactions Associated with Platinum Antineoplastic Agents: A Systematic Review

1Oncology Unit, 3rd Department of Medicine, Sotiria General Hospital, Athens University School of Medicine, Mesogion 152, 115 27 Athens, Greece
2Department of Clinical Oncology, Yale University School of Medicine, New Haven, CT 06510, USA

Received 20 May 2010; Accepted 14 July 2010

Academic Editor: Andrea Bonetti

Copyright © 2010 Nektaria Makrilia et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. E. R. Jamieson and S. J. Lippard, “Structure, recognition, and processing of cisplatin-DNA adducts,” Chemical Reviews, vol. 99, no. 9, pp. 2467–2498, 1999. View at Google Scholar
  2. K. Charalabopoulos, S. Karkabounas, E. Ioachim et al., “Antitumour and toxic effects on Wistar rats of two new platinum complexes,” European Journal of Clinical Investigation, vol. 32, no. 2, pp. 129–133, 2002. View at Publisher · View at Google Scholar
  3. A. Covens, M. Carey, P. Bryson, S. Verma, M. Fung Kee Fung, and M. Johnston, “Systematic review of first-line chemotherapy for newly diagnosed postoperative patients with stage II, III, or IV epithelial ovarian cancer,” Gynecologic Oncology, vol. 85, no. 1, pp. 71–80, 2002. View at Publisher · View at Google Scholar · View at PubMed
  4. E. M. Karapanagiotou, P. G. Boura, G. Papamichalis et al., “Carboplatin-pemetrexed adjuvant chemotherapy in resected Non-small Cell Lung Cancer (NSCLC): a phase II study,” Anticancer Research, vol. 29, no. 10, pp. 4297–4301, 2009. View at Google Scholar
  5. V. Georgoulias, A. Agelidou, K. Syrigos et al., “Second-line treatment with irinotecan plus cisplatin vs cisplatin of patients with advanced non-small-cell lung cancer pretreated with taxanes and gemcitabine: a multicenter randomised phase II study,” British Journal of Cancer, vol. 93, no. 7, pp. 763–769, 2005. View at Publisher · View at Google Scholar · View at PubMed
  6. V. Georgoulias, A. Ardavanis, X. Tsiafaki et al., “Vinorelbine plus cisplatin versus docetaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III randomized trial,” Journal of Clinical Oncology, vol. 23, no. 13, pp. 2937–2945, 2005. View at Publisher · View at Google Scholar · View at PubMed
  7. M. Ignatiadis, D. Mavroudis, M. Veslemes et al., “Sequential versus alternating administration of cisplatin/etoposide and topotecan as first-line treatment in extensive-stage small-cell lung cancer: preliminary results of a phase III trial of the hellenic oncology research group,” Clinical Lung Cancer, vol. 7, no. 3, pp. 183–189, 2005. View at Google Scholar
  8. D. Pectasides, E. Samantas, G. Fountzilas et al., “Combination chemotherapy with cisplatin, etoposide and irinotecan in patients with extensive small-cell lung cancer: a phase II study of the Hellenic Co-operative Oncology Group,” Lung Cancer, vol. 58, no. 3, pp. 355–361, 2007. View at Publisher · View at Google Scholar · View at PubMed
  9. A. Charpidou, S. Tsagouli, S. Tsimpoukis et al., “Triplet combination of carboplatin, irinotecan, and etoposide in the first-line treatment of extensive small-cell lung cancer: a single-institution phase II study,” Anti-Cancer Drugs, vol. 21, no. 6, pp. 651–655, 2010. View at Publisher · View at Google Scholar · View at PubMed
  10. N. Katirtzoglou, I. Gkiozos, N. Makrilia et al., “Carboplatin plus pemetrexed as first-line treatment of patients with malignant pleural mesothelioma: a phase II study,” Clinical Lung Cancer, vol. 11, no. 1, pp. 30–35, 2010. View at Publisher · View at Google Scholar · View at PubMed
  11. N. Androulakis, G. Aravantinos, K. Syrigos et al., “Oxaliplatin as first-line treatment in inoperable biliary tract carcinoma: a multicenter phase II study,” Oncology, vol. 70, no. 4, pp. 280–284, 2006. View at Publisher · View at Google Scholar · View at PubMed
  12. N. Ziras, A. Potamianou, I. Varthalitis et al., “Multicenter phase II study of gemcitabine and oxaliplatin (GEMOX) as second-line chemotherapy in colorectal cancer patients pretreated with 5-fluorouracil plus irinotecan,” Oncology, vol. 70, no. 2, pp. 106–114, 2006. View at Publisher · View at Google Scholar · View at PubMed
  13. N. Androulakis, K. Syrigos, A. Polyzos et al., “Oxaliplatin for pretreated patients with advanced or metastatic pancreatic cancer: a multicenter phase II study,” Cancer Investigation, vol. 23, no. 1, pp. 9–12, 2005. View at Publisher · View at Google Scholar
  14. A. Polyzos, K. Syrigos, J. Stergiou et al., “Phase I trial of weekly docetaxel with a 4-weekly cisplatin administration in patients with advanced gastric carcinoma,” Cancer Chemotherapy and Pharmacology, vol. 55, no. 5, pp. 466–470, 2005. View at Publisher · View at Google Scholar · View at PubMed
  15. K. N. Syrigos, D. Karachalios, E. M. Karapanagiotou, C. M. Nutting, L. Manolopoulos, and K. J. Harrington, “Head and neck cancer in the elderly: an overview on the treatment modalities,” Cancer Treatment Reviews, vol. 35, no. 3, pp. 237–245, 2009. View at Publisher · View at Google Scholar · View at PubMed
  16. D. Y. Yu, G. V. H. Dahl, R. S. Shames, and P. G. Fisher, “Weekly dosing of carboplatin increases risk of allergy in children,” Journal of Pediatric Hematology/Oncology, vol. 23, no. 6, pp. 349–352, 2001. View at Publisher · View at Google Scholar
  17. L. Lafay-Cousin, L. Sung, A.-S. Carret et al., “Carboplatin hypersensitivity reaction in pediatric patients with low-grade glioma: a canadian pediatric brain tumor consortium experience,” Cancer, vol. 112, no. 4, pp. 892–899, 2008. View at Publisher · View at Google Scholar · View at PubMed
  18. M. Markman, A. Kennedy, K. Webster, B. Kulp, G. Peterson, and J. Belinson, “Continued chemosensitivity to cisplatin/carboplatin in ovarian carcinoma despite treatment with multiple prior platinum-based regimens,” Gynecologic Oncology, vol. 65, no. 3, pp. 434–436, 1997. View at Publisher · View at Google Scholar · View at PubMed
  19. S. Kakolyris, N. Ziras, L. Vamvakas et al., “Gemcitabine plus oxaliplatin combination (GEMOX regimen) in pretreated patients with advanced non-small cell lung cancer (NSCLC): a multicenter phase II study,” Lung Cancer, vol. 54, no. 3, pp. 347–352, 2006. View at Publisher · View at Google Scholar · View at PubMed
  20. R. F. Ozols, B. N. Bundy, B. E. Greer et al., “Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study,” Journal of Clinical Oncology, vol. 21, no. 17, pp. 3194–3200, 2003. View at Publisher · View at Google Scholar · View at PubMed
  21. K. N. Syrigos, J. Vansteenkiste, P. Parikh et al., “Prognostic and predictive factors in a randomized phase III trial comparing cisplatin-pemetrexed versus cisplatin-gemcitabine in advanced non-small-cell lung cancer,” Annals of Oncology, vol. 21, no. 3, pp. 556–561, 2010. View at Publisher · View at Google Scholar · View at PubMed
  22. I. Gkiozos, A. Charpidou, and K. Syrigos, “Developments in the treatment of non-small cell lung cancer,” Anticancer Research, vol. 27, no. 4 C, pp. 2823–2827, 2007. View at Google Scholar
  23. J. Souglakos, K. Syrigos, A. Potamianou et al., “Combination of irinotecan (CPT-11) plus oxaliplatin (L-OHP) as first-line treatment in locally advanced or metastatic gastric cancer: a multicentre phase II trial,” Annals of Oncology, vol. 15, no. 8, pp. 1204–1209, 2004. View at Publisher · View at Google Scholar · View at PubMed
  24. A. T. Dimou, K. N. Syrigos, and M. W. Saif, “Neuroendocrine tumors of the pancreas: what's new,” Journal of the Pancreas, vol. 11, no. 2, pp. 135–138, 2010, highlights from the "2010 ASCO Gastrointestinal Cancers Symposium". View at Google Scholar
  25. A. S. Strimpakos, K. N. Syrigos, and M. W. Saif, “Translational research in pancreatic cancer,” Journal of the Pancreas, vol. 11, no. 2, pp. 124–127, 2010, highlights from the "2010 ASCO Gastrointestinal Cancers Symposium". View at Google Scholar
  26. A. S. Strimpakos, K. N. Syrigos, and M. W. Saif, “Pharmacogenetics in pancreatic cancer. Highlights from the "45th ASCO Annual Meeting". Orlando, FL, USA. May 29 - June 2, 2009,” Journal of the Pancreas, vol. 10, no. 4, pp. 357–360, 2009. View at Google Scholar
  27. A. Strimpakos, M. W. Saif, and K. N. Syrigos, “Pancreatic cancer: from molecular pathogenesis to targeted therapy,” Cancer and Metastasis Reviews, vol. 27, no. 3, pp. 495–522, 2008. View at Publisher · View at Google Scholar · View at PubMed
  28. K. N. Syrigos, D. Sitara, E. Georgiou, and K. J. Harrington, “Cytotoxic therapy of gastroenteropancreatic (GEP) tumors,” Anticancer Research, vol. 22, no. 2 B, pp. 1311–1314, 2002. View at Google Scholar
  29. E. Syrigou, N. Makrilia, I. Koti, M. W. Saif, and K. N. Syrigos, “Hypersensitivity reactions to antineoplastic agents: an overview,” Anti-Cancer Drugs, vol. 20, no. 1, pp. 1–6, 2009. View at Publisher · View at Google Scholar · View at PubMed
  30. K. M. Zanotti, L. A. Rybicki, A. W. Kennedy et al., “Carboplatin skin testing: a skin-testing protocol for predicting hypersensitivity to carboplatin chemotherapy,” Journal of Clinical Oncology, vol. 19, no. 12, pp. 3126–3129, 2001. View at Google Scholar
  31. M. B. Callahan, J. A. Lachance, R. L. Stone, J. Kelsey, L. W. Rice, and A. A. Jazaeri, “Use of cisplatin without desensitization after carboplatin hypersensitivity reaction in epithelial ovarian and primary peritoneal cancer,” American Journal of Obstetrics and Gynecology, vol. 197, no. 2, pp. 199.e1–199.e5, 2007. View at Publisher · View at Google Scholar · View at PubMed
  32. M. Markman, A. Kennedy, K. Webster et al., “Clinical features of hypersensitivity reactions to carboplatin,” Journal of Clinical Oncology, vol. 17, no. 4, pp. 1141–1145, 1999. View at Google Scholar
  33. P. G. Rose, N. Fusco, M. Smrekar, K. Mossbruger, and M. Rodriguez, “Successful administration of carboplatin in patients with clinically documented carboplatin hypersensitivity,” Gynecologic Oncology, vol. 89, no. 3, pp. 429–433, 2003. View at Publisher · View at Google Scholar
  34. R. O'Cearbhaill, Q. Zhou, A. Iasonos et al., “The prophylactic conversion to an extended infusion schedule and use of premedication to prevent hypersensitivity reactions in ovarian cancer patients during carboplatin retreatment,” Gynecologic Oncology, vol. 116, no. 3, pp. 326–331, 2010. View at Publisher · View at Google Scholar · View at PubMed
  35. P. A. Kosmidis, H. P. Kalofonos, C. Christodoulou et al., “Paclitaxel and gemcitabine versus carboplatin and gemcitabine in patients with advanced non-small-cell lung cancer. A phase III study of the Hellenic Cooperative Oncology Group,” Annals of Oncology, vol. 19, no. 1, pp. 115–122, 2008. View at Publisher · View at Google Scholar · View at PubMed
  36. E. M. Karapanagiotou, A. Charpidou, I. Tzannou et al., “A phase II study of sequential docetaxel and gemcitabine followed by docetaxel and carboplatin as first-line therapy for non-small cell lung cancer,” Medical Oncology, vol. 25, no. 3, pp. 303–308, 2008. View at Publisher · View at Google Scholar · View at PubMed
  37. V. Georgoulias, A. Ardavanis, A. Agelidou et al., “Docetaxel versus docetaxel plus cisplatin as front-line treatment of patients with advanced non-small-cell lung cancer: a randomized, multicenter phase III trial,” Journal of Clinical Oncology, vol. 22, no. 13, pp. 2602–2609, 2004. View at Publisher · View at Google Scholar · View at PubMed
  38. H. Kook, K. M. Kim, S. H. Choi et al., “Life-threatening carboplatin hypersensitivity during conditioning for autologous PBSC transplantation: successful rechallenge after desensitization,” Bone Marrow Transplantation, vol. 21, no. 7, pp. 727–729, 1998. View at Google Scholar
  39. S. Sliesoraitis and P. J. Chikhale, “Carboplatin hypersensitivity,” International Journal of Gynecological Cancer, vol. 15, no. 1, pp. 13–18, 2005. View at Publisher · View at Google Scholar · View at PubMed
  40. H. Sugimoto, T. Iwamoto, Y. Murashima, T. Tabata, N. Sagawa, and M. Okuda, “Risk factors contributing to the development of carboplatin-related delayed hypersensitivity reactions in Japanese patients with gynecologic cancers,” Cancer Chemotherapy and Pharmacology, 2010. In press.
  41. A. V. Hoekstra, J. A. Hurteau, C. V. Kirschner, and G. C. Rodriguez, “The combination of monthly carboplatin and weekly paclitaxel is highly active for the treatment of recurrent ovarian cancer,” Gynecologic Oncology, vol. 115, no. 3, pp. 377–381, 2009. View at Publisher · View at Google Scholar · View at PubMed
  42. J. S. Morgan, M. Adams, and M. D. Mason, “Hypersensitivity reactions to carboplatin given to patients with relapsed ovarian carcinoma,” European Journal of Cancer A, vol. 30, no. 8, pp. 1205–1206, 1994. View at Publisher · View at Google Scholar
  43. C. Koren, R. Yerushalmi, A. Katz, H. Malik, A. Sulkes, and E. Fenig, “Hypersensitivity reaction to cisplatin during chemoradiation therapy for gynecologic malignancy,” American Journal of Clinical Oncology, vol. 25, no. 6, pp. 625–626, 2002. View at Publisher · View at Google Scholar
  44. M. A. Bautista, W. T. Stevens, C.-S. Chen, B. R. Curtis, R. H. Aster, and C.-T. Hsueh, “Hypersensitivity reaction and acute immune-mediated thrombocytopenia from oxaliplatin: two case reports and a review of the literature,” Journal of Hematology and Oncology, vol. 3, article 12, 2010. View at Publisher · View at Google Scholar · View at PubMed
  45. Y. Shibata, H. Ariyama, E. Baba et al., “Oxaliplatin-induced allergic reaction in patients with colorectal cancer in Japan,” International Journal of Clinical Oncology, vol. 14, no. 5, pp. 397–401, 2009. View at Publisher · View at Google Scholar · View at PubMed
  46. B. H. Kim, T. Bradley, J. Tai, and D. R. Budman, “Hypersensitivity to oxaliplatin: an investigation of incidence and risk factors, and literature review,” Oncology, vol. 76, no. 4, pp. 231–238, 2009. View at Publisher · View at Google Scholar · View at PubMed
  47. A. A. Shlebak, P. I. Clark, and J. A. Green, “Hypersensitivity and cross-reactivity to cisplatin and analogues,” Cancer Chemotherapy and Pharmacology, vol. 35, no. 4, pp. 349–351, 1995. View at Publisher · View at Google Scholar
  48. C. Tournigand, F. Maindrault-Goebel, C. Louvet, A. de Gramont, and M. Krulik, “Severe anaphylactic reactions to oxaliplatin,” European Journal of Cancer, vol. 34, no. 8, pp. 1297–1298, 1998. View at Publisher · View at Google Scholar
  49. J. Medioni, M. A. Coulon, J. F. Morere, F. Hennebelle, S. Piperno-Neumann, and J. L. Breau, “Anaphylaxis after oxaliplatin,” Annals of Oncology, vol. 10, no. 5, p. 610, 1999. View at Google Scholar
  50. A. Abe, H. Ikawa, and S. Ikawa, “Desensitization treatment with cisplatin after carboplatin hypersensitivity reaction in gynecologic cancer,” Journal of Medical Investigation, vol. 57, no. 1-2, pp. 163–167, 2010. View at Google Scholar
  51. R. Gomez, P. Harter, H.-J. Lück et al., “Carboplatin hypersensitivity does introduction of skin test and desensitization reliably predict and avoid the problem? A prospective single-center study,” International Journal of Gynecological Cancer, vol. 19, no. 7, pp. 1284–1287, 2009. View at Publisher · View at Google Scholar · View at PubMed
  52. P. E. Hesterberg, A. Banerji, E. Oren et al., “Risk stratification for desensitization of patients with carboplatin hypersensitivity: clinical presentation and management,” Journal of Allergy and Clinical Immunology, vol. 123, no. 6, pp. 1262–1267, 2009. View at Publisher · View at Google Scholar · View at PubMed
  53. M. C. Castells, N. M. Tennant, D. E. Sloane et al., “Hypersensitivity reactions to chemotherapy: outcomes and safety of rapid desensitization in 413 cases,” Journal of Allergy and Clinical Immunology, vol. 122, no. 3, pp. 574–580, 2008. View at Publisher · View at Google Scholar · View at PubMed
  54. R. Confino-Cohen, A. Fishman, M. Altaras, and A. Goldberg, “Successful carboplatin desensitization in patients with proven carboplatin allergy,” Cancer, vol. 104, no. 3, pp. 640–643, 2005. View at Publisher · View at Google Scholar · View at PubMed
  55. C.-W. Lee, U. A. Matulonis, and M. C. Castells, “Rapid inpatient/outpatient desensitization for chemotherapy hypersensitivity: standard protocol effective in 57 patients for 255 courses,” Gynecologic Oncology, vol. 99, no. 2, pp. 393–399, 2005. View at Publisher · View at Google Scholar · View at PubMed
  56. M. Markman, F. Hsieh, K. Zanotti et al., “Initial experience with a novel desensitization strategy for carboplatin-associated hypersensitivity reactions: carboplatin-hypersensitivity reactions,” Journal of Cancer Research and Clinical Oncology, vol. 130, no. 1, pp. 25–28, 2004. View at Publisher · View at Google Scholar · View at PubMed
  57. R. Jones, M. Ryan, and M. Friedlander, “Carboplatin hypersensitivity reactions: re-treatment with cisplatin desensitisation,” Gynecologic Oncology, vol. 89, no. 1, pp. 112–115, 2003. View at Publisher · View at Google Scholar
  58. E. I. Syrigou, E. M. Karapanagiotou, C. V. Alamara, P. G. Boura, M. W. Saif, and K. N. Syrigos, “Hypersensitivity reactions to oxaliplatin: a retrospective study and the development of a desensitization protocol,” Clinical Colorectal Cancer, vol. 8, no. 2, pp. 106–109, 2009. View at Publisher · View at Google Scholar · View at PubMed
  59. H. Nozawa, Y. Muto, and Y. Yamada, “Desensitization to oxaliplatin with two stages of premedication in a patient with metastatic rectal cancer,” Clinical Therapeutics, vol. 30, no. 6, pp. 1160–1165, 2008. View at Publisher · View at Google Scholar · View at PubMed
  60. S. H. Wrzesinski, M. L. McGurk, C. T. Donovan, T. M. Ferencz, and M. W. Saif, “Successful desensitization to oxaliplatin with incorporation of calcium gluconate and magnesium sulfate,” Anti-Cancer Drugs, vol. 18, no. 6, pp. 721–724, 2007. View at Publisher · View at Google Scholar · View at PubMed
  61. D. A. Edmondson, B. J. Gruling, A. M. Urmanski, S. J. Wong, and M. B. Levy, “Oxaliplatin hypersensitivity: case report and successful repeat desensitization,” American Journal of Therapeutics, vol. 14, no. 1, pp. 116–118, 2007. View at Publisher · View at Google Scholar · View at PubMed
  62. T. Herrero, P. Tornero, S. Infante et al., “Diagnosis and management of hypersensitivity reactions caused by oxaliplatin,” Journal of Investigational Allergology and Clinical Immunology, vol. 16, no. 5, pp. 327–330, 2006. View at Google Scholar
  63. L. Mis, N. H. Fernando, H. I. Hurwitz, and M. A. Morse, “Successful desensitization to oxaliplatin,” Annals of Pharmacotherapy, vol. 39, no. 5, pp. 966–969, 2005. View at Publisher · View at Google Scholar · View at PubMed
  64. K.-H. Lim, M.-J. Huang, H.-C. Lin et al., “Hypersensitivity reactions to oxaliplatin: a case report and the success of a continuous infusional desensitization schedule,” Anti-Cancer Drugs, vol. 15, no. 6, pp. 605–607, 2004. View at Publisher · View at Google Scholar
  65. D. Gammon, P. Bhargava, and M. J. McCormick, “Hypersensitivity reactions to oxaliplatin and the application of a desensitization protocol,” Oncologist, vol. 9, no. 5, pp. 546–549, 2004. View at Publisher · View at Google Scholar · View at PubMed
  66. B. Schüll, G. V. Kornek, and W. Scheithauer, “Idiosyncratic reaction after oxaliplatin: circumvention by use of a continuous infusional administration schedule,” Annals of Oncology, vol. 12, no. 11, pp. 1653–1654, 2001. View at Google Scholar
  67. A. J. Newman Taylor, P. Cullinan, P. A. Lympany, J. M. Harris, R. J. Dowdeswell, and R. M. Du Bois, “Interaction of HLA phenotype and exposure intensity in sensitization to complex platinum salts,” American Journal of Respiratory and Critical Care Medicine, vol. 160, no. 2, pp. 435–438, 1999. View at Google Scholar
  68. M. Markman, K. Zanotti, B. Kulp, G. Peterson, and M. Markman, “Relationship between a history of systemic allergic reactions and risk of subsequent carboplatin hypersensitivity,” Gynecologic Oncology, vol. 89, no. 3, pp. 514–516, 2003. View at Publisher · View at Google Scholar
  69. A. Gadducci, R. Tana, G. Teti, G. Zanca, A. Fanucchi, and A. R. Genazzani, “Analysis of the pattern of hypersensitivity reactions in patients receiving carboplatin retreatment for recurrent ovarian cancer,” International Journal of Gynecological Cancer, vol. 18, no. 4, pp. 615–620, 2008. View at Publisher · View at Google Scholar
  70. M. Navo, A. Kunthur, M. L. Badell et al., “Evaluation of the incidence of carboplatin hypersensitivity reactions in cancer patients,” Gynecologic Oncology, vol. 103, no. 2, pp. 608–613, 2006. View at Publisher · View at Google Scholar · View at PubMed
  71. J. R. Schwartz, C. Bandera, A. Bradley et al., “Does the platinum-free interval predict the incidence or severity of hypersensitivity reactions to carboplatin? The experience from Women and Infants' Hospital,” Gynecologic Oncology, vol. 105, no. 1, pp. 81–83, 2007. View at Publisher · View at Google Scholar · View at PubMed
  72. A. Bamias, K. Syrigos, G. Fountzilas et al., “Intensified bimonthly cisplatin with bolus 5-fluorouracil, continuous 5-fluorouracil and high-dose leucovorin (LV5FU2) in patients with advanced gastrointestinal carcinomas: a phase I dose-finding and pharmacokinetic study,” American Journal of Clinical Oncology, vol. 27, no. 5, pp. 465–471, 2004. View at Publisher · View at Google Scholar
  73. Y. Ichikawa, A. Goto, S. Hirokawa et al., “Allergic reactions to oxaliplatin in a single Institute in Japan,” Japanese Journal of Clinical Oncology, vol. 39, no. 9, pp. 616–620, 2009. View at Publisher · View at Google Scholar · View at PubMed
  74. E. Pujade-Lauraine, U. Wagner, E. Aavall-Lundqvist et al., “Pegylated liposomal Doxorubicin and Carboplatin compared with Paclitaxel and Carboplatin for patients with platinum-sensitive ovarian cancer in late relapse,” Journal of Clinical Oncology, vol. 28, no. 20, pp. 3323–3329, 2010. View at Publisher · View at Google Scholar · View at PubMed
  75. M. Markman, J. Moon, S. Wilczynski et al., “Single agent carboplatin versus carboplatin plus pegylated liposomal doxorubicin in recurrent ovarian cancer: final survival results of a SWOG (S0200) phase 3 randomized trial,” Gynecologic Oncology, vol. 116, no. 3, pp. 323–325, 2010. View at Publisher · View at Google Scholar · View at PubMed
  76. G. M. Shepherd, “Hypersensitivity reactions to chemotherapeutic drugs,” Clinical Reviews in Allergy and Immunology, vol. 24, no. 3, pp. 253–262, 2003. View at Publisher · View at Google Scholar · View at PubMed
  77. E. Syrigou, K. Syrigos, and M. W. Saif, “Hypersensitivity reactions to oxaliplatin and other antineoplastic agents,” Current Allergy and Asthma Reports, vol. 8, no. 1, pp. 56–62, 2008. View at Publisher · View at Google Scholar
  78. A. Goldberg, R. Confino-Cohen, A. Fishman, Y. Beyth, and M. Altaras, “A modified, prolonged desensitization protocol in carboplatin allergy,” Journal of Allergy and Clinical Immunology, vol. 98, no. 4, pp. 841–843, 1996. View at Publisher · View at Google Scholar
  79. E. Enrique, T. Malek, J. V. Castelló, and J. A. de Mateo, “Usefulness of skin testing with platinum salts to demonstrate lack of cross-reactivity between carboplatin and cisplatin,” Annals of Allergy, Asthma and Immunology, vol. 100, no. 1, p. 86, 2008. View at Google Scholar
  80. O. Cromwell, J. Pepys, W. E. Parish, and E. G. Hughes, “Specific IgE antibodies to platinum salts in sensitized workers,” Clinical Allergy, vol. 9, no. 2, pp. 109–117, 1979. View at Google Scholar
  81. D. Santini, G. Tonini, A. Salerno et al., “Idiosyncratic reaction after oxaliplatin infusion,” Annals of Oncology, vol. 12, no. 1, pp. 132–133, 2001. View at Publisher · View at Google Scholar
  82. M.-Y. Lee, M.-H. Yang, J.-H. Liu et al., “Severe anaphylactic reactions in patients receiving oxaliplatin therapy: a rare but potentially fatal complication,” Supportive Care in Cancer, vol. 15, no. 1, pp. 89–93, 2007. View at Publisher · View at Google Scholar · View at PubMed
  83. C. Garufi, S. Vaglio, S. Brienza et al., “Immunohemolytic anemia following oxaliplatin administration,” Annals of Oncology, vol. 11, no. 4, p. 497, 2000. View at Publisher · View at Google Scholar
  84. R. R. Thomas, M. G. Quinn, B. Schuler, and J. L. Grem, “Hypersensitivity and idiosyncratic reactions to oxaliplatin,” Cancer, vol. 97, no. 9, pp. 2301–2307, 2003. View at Publisher · View at Google Scholar · View at PubMed
  85. R. S. de Vries, E. J. Mattijssen, and A. A. van Sorge, “Serious delayed hypersensitivity reaction to oxaliplatin,” Annals of Oncology, vol. 17, no. 11, pp. 1723–1724, 2006. View at Publisher · View at Google Scholar · View at PubMed
  86. M. Morgan, D. C. Bowers, R. S. Gruchalla, and D. A. Khan, “Safety and efficacy of repeated monthly carboplatin desensitization,” Journal of Allergy and Clinical Immunology, vol. 114, no. 4, pp. 974–975, 2004. View at Publisher · View at Google Scholar · View at PubMed
  87. A. Vekris, D. Meynard, M.-C. Haaz, M. Bayssas, J. Bonnet, and J. Robert, “Molecular determinants of the cytotoxicity of platinum compounds: the contribution of in silico research,” Cancer Research, vol. 64, no. 1, pp. 356–362, 2004. View at Publisher · View at Google Scholar
  88. D. P. Greene, J. S. Ferriss, and A. A. Jazaeri, “Cisplatin administration following carboplatin desensitization failure in primary peritoneal cancer: a brief report,” Cancer Chemotherapy and Pharmacology, vol. 66, no. 2, pp. 265–267, 2010. View at Publisher · View at Google Scholar · View at PubMed
  89. D. S. Dizon, P. J. Sabbatini, C. Aghajanian, M. L. Hensley, and D. R. Spriggs, “Analysis of patients with epithelial ovarian cancer or fallopian tube carcinoma retreated with cisplatin after the development of a carboplatin allergy,” Gynecologic Oncology, vol. 84, no. 3, pp. 378–382, 2002. View at Publisher · View at Google Scholar · View at PubMed
  90. S. Zweizig, L. D. Roman, and L. I. Muderspach, “Death from anaphylaxis to cisplatin: a case report,” Gynecologic Oncology, vol. 53, no. 1, pp. 121–122, 1994. View at Publisher · View at Google Scholar · View at PubMed
  91. F. Maindrault-Goebel, T. André, C. Tournigand et al., “Allergic-type reactions to oxaliplatin: retrospective analysis of 42 patients,” European Journal of Cancer, vol. 41, no. 15, pp. 2262–2267, 2005. View at Publisher · View at Google Scholar · View at PubMed
  92. S. Potenza, G. Nasti, O. Alessandro, A. Filippelli, F. Rossi, and A. Capuano, “Severe respiratory symptoms to oxaliplatin infusion: a case report of delayed hypersensitivity reaction,” Investigational New Drugs, vol. 28, no. 2, pp. 185–186, 2010. View at Publisher · View at Google Scholar · View at PubMed
  93. M. W. Saif, S. Roy, L. Ledbetter, J. Madison, and K. Syrigos, “Fever as the only manifestation of hypersensitivity reactions associated with oxaliplatin in a patient with colorectal cancer Oxaliplatin-induced hypersensitivity reaction,” World Journal of Gastroenterology, vol. 13, no. 39, pp. 5277–5281, 2007. View at Google Scholar
  94. M. W. Saif, K. I. Syrigos, S. Hotchkiss et al., “Successful desensitization with cetuximab after an infusion reaction to panitumumab in patients with metastatic colorectal cancer,” Cancer Chemotherapy and Pharmacology, vol. 65, no. 1, pp. 107–112, 2009. View at Publisher · View at Google Scholar · View at PubMed
  95. J. M. Montiel Herrera, M. A. Góngora-Melendez, M. L. Pineda-Maldonado et al., “Carboplatin hypersensitivity and desensitization in an infant,” Therapeutic Drug Monitoring, vol. 32, no. 4, pp. 525–528, 2010. View at Google Scholar
  96. M. Markman, “Hypersensitivity reactions to carboplatin,” Gynecologic Oncology, vol. 84, no. 2, pp. 353–354, 2002. View at Google Scholar
  97. A. Polyzos, N. Tsavaris, C. Kosmas et al., “Hypersensitivity reactions to carboplatin administration are common but not always severe: a 10-year experience,” Oncology, vol. 61, no. 2, pp. 129–133, 2001. View at Publisher · View at Google Scholar
  98. G. Porzio, P. Marchetti, I. Paris, F. Narducci, E. Ricevuto, and C. Ficorella, “Hypersensitivity reaction to carboplatin: successful resolution by replacement with cisplatin,” European Journal of Gynaecological Oncology, vol. 23, no. 4, pp. 335–336, 2002. View at Google Scholar
  99. M. J. Kandel, A. Loehr, P. Harter, A. Traut, K. Gnauert, and A. Du Bois, “Cisplatinum rechallenge in relapsed ovarian cancer patients with platinum reinduction therapy and carboplatin hypersensitivity,” International Journal of Gynecological Cancer, vol. 15, no. 5, pp. 780–784, 2005. View at Publisher · View at Google Scholar · View at PubMed
  100. K. T. Elligers, M. Davies, D. Sanchis, T. Ferencz, and M. W. Saif, “Rechallenge with cisplatin in a patient with pancreatic cancer who developed a hypersensitivity reaction to oxaliplatin. Is skin test useful in this setting?” Journal of the Pancreas, vol. 9, no. 2, pp. 197–202, 2008. View at Google Scholar
  101. A. Ottaiano, R. Tambaro, S. Greggi et al., “Safety of cisplatin after severe hypersensitivity reactions to carboplatin in patients with recurrent ovarian carcinoma,” Anticancer Research, vol. 23, no. 4, pp. 3465–3468, 2003. View at Google Scholar
  102. J. B. Robinson, D. Singh, D. C. Bodurka-Bevers, J. T. Wharton, D. M. Gershenson, and J. K. Wolf, “Hypersensitivity reactions and the utility of oral and intravenous desensitization in patients with gynecologic malignancies,” Gynecologic Oncology, vol. 82, no. 3, pp. 550–558, 2001. View at Publisher · View at Google Scholar · View at PubMed
  103. M. Markman, K. Zanotti, G. Peterson, B. Kulp, K. Webster, and J. Belinson, “Expanded experience with an intradermal skin test to predict for the presence or absence of carboplatin hypersensitivity,” Journal of Clinical Oncology, vol. 21, no. 24, pp. 4611–4614, 2003. View at Publisher · View at Google Scholar · View at PubMed
  104. V. Leguy-Seguin, G. Jolimoy, B. Coudert et al., “Diagnostic and predictive value of skin testing in platinum salt hypersensitivity,” Journal of Allergy and Clinical Immunology, vol. 119, no. 3, pp. 726–730, 2007. View at Publisher · View at Google Scholar · View at PubMed
  105. E. Syrigou, N. Makrilia, A. Vassias et al., “Administration of cisplatin in three patients with carboplatin hypersensitivity: is skin testing useful?” Anti-Cancer Drugs, vol. 21, no. 3, pp. 333–338, 2010. View at Publisher · View at Google Scholar · View at PubMed
  106. A. Gowda, R. Goel, J. Berdzik, C. G. Leichman, and M. Javle, “Hypersensitivity reactions to oxaliplatin: incidence and management,” Oncology, vol. 18, no. 13, pp. 1671–1675, 2004. View at Google Scholar
  107. G. Brandi, M. A. Pantaleo, C. Galli et al., “Hypersensitivity reactions related to oxaliplatin (OHP),” British Journal of Cancer, vol. 89, no. 3, pp. 477–481, 2003. View at Publisher · View at Google Scholar · View at PubMed
  108. P. Bhargava, D. Gammon, and M. J. McCormick, “Hypersensitivity and idiosyncratic reactions to oxaliplatin,” Cancer, vol. 100, no. 1, pp. 211–212, 2004. View at Publisher · View at Google Scholar · View at PubMed
  109. S. W. K. Siu, R. T. T. Chan, and G. K. H. Au, “Hypersensitivity reactions to oxaliplatin: experience in a single institute,” Annals of Oncology, vol. 17, no. 2, pp. 259–261, 2006. View at Publisher · View at Google Scholar · View at PubMed
  110. L. Meyer, T. Zuberbier, M. Worm, H. Oettle, and H. Riess, “Hypersensitivity reactions to oxaliplatin: cross-reactivity to carboplatin and the introduction of a desensitization schedule,” Journal of Clinical Oncology, vol. 20, no. 4, pp. 1146–1147, 2002. View at Google Scholar
  111. F. Lévi, R. Zidani, and J.-L. Misset, “Randomised multicentre trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer,” Lancet, vol. 350, no. 9079, pp. 681–686, 1997. View at Publisher · View at Google Scholar
  112. C. Garufi, A. Cristaudo, B. Vanni et al., “Skin testing and hypersensitivity reactions to oxaliplatin,” Annals of Oncology, vol. 14, no. 3, pp. 497–498, 2003. View at Publisher · View at Google Scholar